Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.
| Condition |
|---|
|
Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic |
whole blood
| Estimated Enrollment: | 10000 |
| Study Start Date: | January 2003 |
| Estimated Study Completion Date: | January 2025 |
| Estimated Primary Completion Date: | January 2025 (Final data collection date for primary outcome measure) |
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
primary care clinic
Inclusion Criteria:
- cancer
Exclusion Criteria:
- not able to comply with follow-up
Contacts and Locations| Contact: Philippe Lambin, Prof PHD | 31 (0) 088 44 55 666 | philippe.lambin@maastro.nl |
| Contact: Dirk De Ruysscher, Prof PHD | 31 (0) 088 44 55 666 | dirk.deruysscher@maastro.nl |
| Netherlands | |
| Maastricht Radiation Oncology | Recruiting |
| Maastricht, Limburg, Netherlands | |
| Contact: Dirk De Ruysscher, Prof PHD 31 (0) 88 44 55 666 dirk.deruysscher@maastro.nl | |
| Contact: Philippe Lambin, Prof PHD 31 (0) 88 44 55 666 philippe.lambin@maastro.nl | |
| Principal Investigator: Dirk De Ruysscher, Prof PHD | |
| Principal Investigator: | Dirk De Ruysscher, Prof PHD | CCMO |
More Information
No publications provided by Maastricht Radiation Oncology
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Maastricht Radiation Oncology |
| ClinicalTrials.gov Identifier: | NCT01084785 History of Changes |
| Obsolete Identifiers: | NCT00157352, NCT00157365, NCT00157391, NCT00157404, NCT00157417, NCT00157430, NCT00157443, NCT00157456, NCT00157469, NCT00157495, NCT00181337, NCT00181376, NCT00181389, NCT00181402, NCT00181415, NCT00181428, NCT00181441, NCT00181454, NCT00181467, NCT00181480, NCT00181493, NCT00181519, NCT01067872 |
| Other Study ID Numbers: | 08-06-23/01 |
| Study First Received: | March 10, 2010 |
| Last Updated: | December 27, 2012 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Maastricht Radiation Oncology:
|
Cancer genomics proteomics |
ClinicalTrials.gov processed this record on June 17, 2013